Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Income (2016 - 2025)

Agios Pharmaceuticals (AGIO) has disclosed Net Income for 12 consecutive years, with -$108.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 10.17% year-over-year to -$108.2 million, compared with a TTM value of -$414.7 million through Dec 2025, down 162.0%, and an annual FY2025 reading of -$412.8 million, down 161.27% over the prior year.
  • Net Income was -$108.2 million for Q4 2025 at Agios Pharmaceuticals, down from -$103.4 million in the prior quarter.
  • Across five years, Net Income topped out at $2.0 billion in Q1 2021 and bottomed at -$112.5 million in Q2 2025.
  • Average Net Income over 4 years is $116.2 million, with a median of -$88.0 million recorded in 2023.
  • The sharpest move saw Net Income surged 4382.87% in 2021, then tumbled 110.91% in 2025.
  • Year by year, Net Income stood at $4.0 million in 2021, then crashed by 2567.85% to -$97.7 million in 2023, then dropped by 0.53% to -$98.2 million in 2024, then fell by 10.17% to -$108.2 million in 2025.
  • Business Quant data shows Net Income for AGIO at -$108.2 million in Q4 2025, -$103.4 million in Q3 2025, and -$112.5 million in Q2 2025.